Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mahmoud Kandeel. (2023) An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery. Expert Opinion on Drug Discovery 18:4, pages 385-400.
Read now
Read now
Sreus A. G. Naidu, Ghulam Mustafa, Roger A. Clemens & A. Satyanarayan Naidu. (2023) Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2. Journal of Dietary Supplements 20:2, pages 254-283.
Read now
Read now
Long G Wang & Luxi Wang. (2022) Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2. ImmunoTargets and Therapy 11, pages 23-35.
Read now
Read now
Pasquale Pagliano, Carmine Sellitto, Tiziana Ascione, Giuliana Scarpati, Veronica Folliero, Ornella Piazza, Gianluigi Franci, Amelia Filippelli & Valeria Conti. (2022) The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opinion on Drug Discovery 17:12, pages 1299-1311.
Read now
Read now
Claudiu T. Supuran. (2021) Coronaviruses. Expert Opinion on Therapeutic Patents 31:4, pages 291-294.
Read now
Read now
Articles from other publishers (62)
Mingxiao Gu, Sudan Sun, Qidong You & Lei Wang. (2023) Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022. Molecules 28:24, pages 7941.
Crossref
Crossref
Brittany A. Comunale, Robin J. Larson, Erin Jackson-Ward, Aditi Singh, Frances L. Koback & Lilly D. Engineer. (2023) The Functional Implications of Broad Spectrum Bioactive Compounds Targeting RNA-Dependent RNA Polymerase (RdRp) in the Context of the COVID-19 Pandemic. Viruses 15:12, pages 2316.
Crossref
Crossref
Kiran Shehzadi, Afsheen Saba, Mingjia Yu & Jianhua Liang. (2023) Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2. Topics in Current Chemistry 381:5.
Crossref
Crossref
Susital Mal & Subrata Das. (2023) Surfactant‐Mediated Synthesis of Methylene Bridged 6‐Aminouracils: Development of a Greener Protocol, Water Remediation and Preliminary Biological Screening. ChemistrySelect 8:35.
Crossref
Crossref
Mehdi Valipour. (2023)
Therapeutic prospects of naturally occurring p38
MAPK
inhibitors tanshinone
IIA
and pinocembrin for the treatment of
SARS‐CoV
‐2‐induced
CNS
complications
. Phytotherapy Research 37:9, pages 3724-3743.
Crossref
Crossref
Ke-Wei Zhu. (2023) Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials. Frontiers in Pharmacology 14.
Crossref
Crossref
Timofey Komarov, Polina Karnakova, Olga Archakova, Dana Shchelgacheva, Natalia Bagaeva, Mariia Popova, Polina Karpova, Kira Zaslavskaya, Petr Bely & Igor Shohin. (2023) Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma. Biomedicines 11:9, pages 2356.
Crossref
Crossref
Amal Vijay, Venkata Sai Sreyas Adury & Arnab Mukherjee. (2023) Targeting RdRp of SARS-CoV-2 with De Novo Molecule Generation. ACS Applied Bio Materials.
Crossref
Crossref
Divakar Vishwanath, Anita Shete-Aich, Manjunath B. Honnegowda, Mahesh Padukudru Anand, Saravana Babu Chidambaram, Gajanan Sapkal, Basappa Basappa & Pragya D. Yadav. (2023) Discovery of Hybrid Thiouracil–Coumarin Conjugates as Potential Novel Anti-SARS-CoV-2 Agents Targeting the Virus’s Polymerase “RdRp” as a Confirmed Interacting Biomolecule. ACS Omega 8:30, pages 27056-27066.
Crossref
Crossref
Tuhin Mukherjee, Payel Mal, Abhay Kumar Upadhyay, Satyajit Mohanty, Nikita Nayak, Ravi Pratap Singh, Ashok Pattnaik, Tanisha Das & Sourav Basak. (2023) Safety Profile of Molnupiravir with Significant Effect on COVID-19: A
Review. Current Drug Therapy 18:3, pages 183-193.
Crossref
Crossref
Emmanuelle Bignon, Stéphanie Grandemange, Elise Dumont & Antonio Monari. (2023) How SARS-CoV-2 Alters the Regulation of Gene Expression in Infected Cells. The Journal of Physical Chemistry Letters 14:13, pages 3199-3207.
Crossref
Crossref
Mohamed S. Bekheit, Siva S. Panda & Adel S. Girgis. (2023) Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2. European Journal of Medicinal Chemistry 252, pages 115292.
Crossref
Crossref
Mariappan. AThanalakshmi. JS. SundarRadha SMeenakumari RKaaruniya. G. (2023) In-silico Studies of Active Phytochemicals from Siddha Medicinal Herbs of Karisalai Chooranam against SARS-CoV-2 main Protease (3CLpro), RNA Dependent RNA Polymerase and Angiotensin-Converting Enzyme II Receptor. Research Journal of Pharmacy and Technology, pages 1033-1040.
Crossref
Crossref
Morteza Zaboli Mahdiabadi, Chiman Karami, Elham Saber, Mostafa Kamali, Amirhossein Orandi, Alireza Dadashi, Mohsen Aminizadeh, Sadegh Ahmadi-Mazhin, Saeed Khorramnia & Nouri Mehdi. (2023) EFFECTIVENESS OF MOLNUPIRAVIR IN THE TREATMENT OF PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS. Studies in Medical Sciences 33:12, pages 857-867.
Crossref
Crossref
Nataliya Miropolskaya, Maxim Kozlov, Ivan Petushkov, Maria Prostova, Danil Pupov, Daria Esyunina, Sergey Kochetkov & Andrey Kulbachinskiy. (2023) Effects of natural polymorphisms in SARS-CoV-2 RNA-dependent RNA polymerase on its activity and sensitivity to inhibitors in vitro. Biochimie 206, pages 81-88.
Crossref
Crossref
Chienhsiu Huang, Tsung-Lung Lu & Lichen Lin. (2023) Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis. Antibiotics 12:2, pages 393.
Crossref
Crossref
Nicoletta Brindani, Federico Munafò, Andrea Menichetti, Elisa Donati, Michela Nigro, Giuliana Ottonello, Andrea Armirotti & Marco De Vivo. (2023) Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors. Bioorganic & Medicinal Chemistry 80, pages 117179.
Crossref
Crossref
Katarina Baralić, Katarina Živančević, Dragica Bozic & Danijela Đukić-Ćosić. 2023. Omics approaches and technologies in COVID-19. Omics approaches and technologies in COVID-19
367
385
.
Michael A. Chary, Alexander F. Barbuto, Sudeh Izadmehr, Marc Tarsillo, Eduardo Fleischer & Michele M. Burns. (2022) COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics). Journal of Medical Toxicology 19:1, pages 26-36.
Crossref
Crossref
Mohandass Kaviya, Irudhayaraj Peatrise Geofferina, Prasad Poornima, Anand Prem Rajan, Balasubramanian Balamuralikrishnan, Meyyazhagan Arun, Naif Abdullah Al-Dhabi, Mariadhas Valan Arasu, Pushparaj Karthika, Subramaniam Kallidass, Shanmugam Ramya & Arumugam Vijaya Anand. 2023. Ethnopharmacology and Drug Discovery for COVID-19: Anti-SARS-CoV-2 Agents from Herbal Medicines and Natural Products. Ethnopharmacology and Drug Discovery for COVID-19: Anti-SARS-CoV-2 Agents from Herbal Medicines and Natural Products
265
316
.
Manoj A. Mangukiya, Pritam V. Bagwe, Aman A. Desai & Shreerang V. Joshi. (2022) DEVELOPMENT AND VALIDATION OF A NOVEL STABILITY INDICATING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR RELATED SUBSTANCES AND ASSAY ANALYSIS OF MOLNUPIRAVIR DRUG SUBSTANCE AND DRUG PRODUCT. Indian Drugs 59:12, pages 55-69.
Crossref
Crossref
Shenghua Gao, Letian Song, Hongtao Xu, Antonios Fikatas, Merel Oeyen, Steven De Jonghe, Fabao Zhao, Lanlan Jing, Dirk Jochmans, Laura Vangeel, Yusen Cheng, Dongwei Kang, Johan Neyts, Piet Herdewijn, Dominique Schols, Peng Zhan & Xinyong Liu. (2022) Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors. Molecules 28:1, pages 160.
Crossref
Crossref
Chiara Stefani, Tobia Fantoni, Michele Bissoli, Jordan Thomas & Alessandra Ruggiero. (2022) HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies. Life 12:12, pages 2089.
Crossref
Crossref
Sibei Lei, Xiaohua Chen, Jieping Wu, Xingmei Duan & Ke Men. (2022) Small molecules in the treatment of COVID-19. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Lina Zhang, Fenju Wei, Jiwei Zhang, Chuanfeng Liu, Nerea López-Carrobles, Xinyong Liu, Luis Menéndez-Arias & Peng Zhan. (2022) Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors. European Journal of Medicinal Chemistry 243, pages 114760.
Crossref
Crossref
Mehran Alavi, M. R. Mozafari, Saba Ghaemi, Morahem Ashengroph, Fatemeh Hasanzadeh Davarani & Mohammadreza Mohammadabadi. (2022) Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study. Biomedicines 10:12, pages 3074.
Crossref
Crossref
Yifan Zhang, Xinglong Zhang, Huiwen Zheng & Longding Liu. (2022) Subgenomic RNAs and Their Encoded Proteins Contribute to the Rapid Duplication of SARS-CoV-2 and COVID-19 Progression. Biomolecules 12:11, pages 1680.
Crossref
Crossref
Xiaoying Xu, Yuheng Chen, Xinyu Lu, Wanlin Zhang, Wenxiu Fang, Luping Yuan & Xiaoyan Wang. (2022) An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges. Biochemical Pharmacology 205, pages 115279.
Crossref
Crossref
Andrea De Vito, Agnese Colpani, Alessandra Bitti, Beatrice Zauli, Maria Chiara Meloni, Marco Fois, Lucia Denti, Sara Bacciu, Claudia Marcia, Ivana Maida, Sergio Babudieri & Giordano Madeddu. (2022) Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience. Journal of Medical Virology 94:11, pages 5582-5588.
Crossref
Crossref
Walid F. Elkhatib, Shereen S. Abdelkareem, Wafaa S. Khalaf, Mona I. Shahin, Dounia Elfadil, Alaa Alhazmi, Ahmed I. El-Batal & Gharieb S. El-Sayyad. (2022) Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting. Virology Journal 19:1.
Crossref
Crossref
Sumit Kumar, Neha Sharma, Willyenne Marilia Dantas, Jessica Catarine Frutuoso do Nascimento, Hannah Maus, Ronaldo Nascimento de Oliveira, Unnat Pandit, Agam P. Singh, Tanja Schirmeister, Puja Panwar Hazari, Lindomar Pena, Poonam & Brijesh Rathi. (2022) A potent candidate against Zika virus infection: Synthesis, bioactivity, radiolabeling and biodistribution studies. New Journal of Chemistry 46:39, pages 18764-18775.
Crossref
Crossref
Behnam Amani, Sara Zareei & Bahman Amani. (2022) Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19. British Journal of Clinical Pharmacology 88:10, pages 4403-4411.
Crossref
Crossref
Ahmed O. Mohammed, Mazin I. Abo-Idrees, Alaa A. Makki, Walaa Ibraheem & Abdulrahim A. Alzain. (2022) Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics. Structural Chemistry 33:5, pages 1553-1567.
Crossref
Crossref
Michela Pontolillo, Claudio Ucciferri, Paola Borrelli, Marta Di Nicola, Jacopo Vecchiet & Katia Falasca. (2022) Molnupiravir as an Early Treatment for COVID-19: A Real Life Study. Pathogens 11:10, pages 1121.
Crossref
Crossref
Emmanuelle Bignon & Antonio Monari. (2022) Modeling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent RNA Polymerase by DFT/MM-MD: An Unusual Active Site Leading to High Replication Rates. Journal of Chemical Information and Modeling 62:17, pages 4261-4269.
Crossref
Crossref
Ghulam Rasool Mangrio, Apichit Maneengam, Zunera Khalid, Tassadaq Hussain Jafar, Ghulam Qadir Chanihoon, Rayan Nassani & Ahsanullah Unar. (2022) RP-HPLC Method Development, Validation, and Drug Repurposing of Sofosbuvir Pharmaceutical Dosage Form: A Multidimensional Study. Environmental Research 212, pages 113282.
Crossref
Crossref
Timsy Uppal, Kai Tuffo, Svetlana Khaiboullina, Sivani Reganti, Mark Pandori & Subhash C. Verma. (2022) Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay. Cell Insight 1:4, pages 100046.
Crossref
Crossref
Yulin Dai, Hui Yu, Qiheng Yan, Bingrui Li, Andi Liu, Wendao Liu, Xiaoqian Jiang, Yejin Kim, Yan Guo & Zhongming Zhao. (2022) Drug-Target Network Study Reveals the Core Target-Protein Interactions of Various COVID-19 Treatments. Genes 13:7, pages 1210.
Crossref
Crossref
Hasan Esat Yücel. (2022) A case of acute renal failure with COVID-19 under Molnupiravir treatment. Medical Science and Discovery 9:6, pages 371-374.
Crossref
Crossref
Xuanting Wang, Chuanjuan Tao, Irina Morozova, Sergey Kalachikov, Xiaoxu Li, Shiv Kumar, James J. Russo & Jingyue Ju. (2022) Identifying Structural Features of Nucleotide Analogues to Overcome SARS-CoV-2 Exonuclease Activity. Viruses 14:7, pages 1413.
Crossref
Crossref
Bing Wang, Dmitri Svetlov, Dylan Bartikofsky, Christiane E. Wobus & Irina Artsimovitch. (2022) Going Retro, Going Viral: Experiences and Lessons in Drug Discovery from COVID-19. Molecules 27:12, pages 3815.
Crossref
Crossref
Sandro G Viveiros Rosa & Wilson C Santos. (2022) Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry. Pharmaceutical Patent Analyst 11:2, pages 57-73.
Crossref
Crossref
Yahiya Y. Syed. (2022) Molnupiravir: First Approval. Drugs 82:4, pages 455-460.
Crossref
Crossref
Qin Ning, Di Wu, Xiaojing Wang, Dong Xi, Tao Chen, Guang Chen, Hongwu Wang, Huiling Lu, Ming Wang, Lin Zhu, Junjian Hu, Tingting Liu, Ke Ma, Meifang Han & Xiaoping Luo. (2022) The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Xuanting Wang, Carolina Q. Sacramento, Steffen Jockusch, Otávio Augusto Chaves, Chuanjuan Tao, Natalia Fintelman-Rodrigues, Minchen Chien, Jairo R. Temerozo, Xiaoxu Li, Shiv Kumar, Wei Xie, Dinshaw J. Patel, Cindy Meyer, Aitor Garzia, Thomas Tuschl, Patrícia T. Bozza, James J. Russo, Thiago Moreno L. Souza & Jingyue Ju. (2022) Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Communications Biology 5:1.
Crossref
Crossref
Fariba Pourkarim, Samira Pourtaghi‐Anvarian & Haleh Rezaee. (2021) Molnupiravir: A new candidate for COVID‐19 treatment. Pharmacology Research & Perspectives 10:1.
Crossref
Crossref
Weizhu Yan, Yanhui Zheng, Xiaotao Zeng, Bin He & Wei Cheng. (2022) Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
J. Carlos Menéndez. (2022) Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective. Molecules 27:3, pages 658.
Crossref
Crossref
Debdoot Basu, Vivek P. Chavda & Anita A. Mehta. (2022) Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery 3, pages 100086.
Crossref
Crossref
Michael D. Waters, Stafford Warren, Claude Hughes, Philip Lewis & Fengyu Zhang. (2022) Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. Environmental and Molecular Mutagenesis 63:1, pages 37-63.
Crossref
Crossref
Yifei Wu, David Crich, Scott D. Pegan, Lei Lou, Madelyn C. Hansen, Carson Booth, Ellison Desrochers, Lauren Nicole Mullininx, Edward B. Starling, Kuan Y. Chang & Zhong-Ru Xie. (2021) Polyphenols as Potential Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp). Molecules 26:24, pages 7438.
Crossref
Crossref
Pooria Asili, Maryam Mirahmad, Ozra Tabatabaei-Malazy, Azadeh Manayi, Elahe Haghighat, Mohammad Mahdavi & Bagher Larijani. (2021) Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. DARU Journal of Pharmaceutical Sciences 29:2, pages 449-467.
Crossref
Crossref
Ching-Chi Lee, Chih-Chia Hsieh & Wen-Chien Ko. (2021) Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent. Antibiotics 10:11, pages 1294.
Crossref
Crossref
Mohd. Imran, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Saleh I. Alaqel, Mohammed Kanan Alshammari, Mohammed M. Alshehri, Ahmed Subeh Alshrari, Alreshidi Mateq Ali, Ahmed Muteb Al-shammeri, Bushra Dhuhayyan Alhazmi, Aishah Ali Harshan, Md. Tauquir Alam & Abida Abida. (2021) Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules 26:19, pages 5795.
Crossref
Crossref
Brandon Malone & Elizabeth A. Campbell. (2021) Molnupiravir: coding for catastrophe. Nature Structural & Molecular Biology 28:9, pages 706-708.
Crossref
Crossref
Florian Kabinger, Carina Stiller, Jana Schmitzová, Christian Dienemann, Goran Kokic, Hauke S. Hillen, Claudia Höbartner & Patrick Cramer. (2021) Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nature Structural & Molecular Biology 28:9, pages 740-746.
Crossref
Crossref
Milan Dejmek, Eva Konkoľová, Luděk Eyer, Petra Straková, Pavel Svoboda, Michal Šála, Kateřina Krejčová, Daniel Růžek, Evzen Boura & Radim Nencka. (2021) Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication. Viruses 13:8, pages 1585.
Crossref
Crossref
Didier F. Vargas, Enrique L. Larghi & Teodoro S. Kaufman. (2021) Evolution of the Synthesis of Remdesivir. Classical Approaches and Most Recent Advances. ACS Omega 6:30, pages 19356-19363.
Crossref
Crossref
Mohd. Imran, Ahmed Subeh Alshrari, Syed Mohammed Basheeruddin Asdaq & Abida. (2021) Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review. Journal of Infection and Public Health 14:8, pages 1075-1086.
Crossref
Crossref
Erman Salih İSTİFLİ. (2021) In Silico Screening of the Phenolic Compound Oleuropein and Its Hydrolysis Product 3-Hydroxytyrosol Against Certain Structural and Non-Structural Proteins of SARS-CoV- 2Fenolik Bileşik Oleuropein ve Hidroliz Ürünü 3-Hidroksitirozol'ün SARS-CoV-2'nin Bazı Yapısal ve Yapısal Olmayan Proteinlerine Karşı In Siliko Etkinliği. Türk Tarım ve Doğa Bilimleri Dergisi 8:3, pages 824-833.
Crossref
Crossref
Nadezhda Palko, Maria Grishina & Vladimir Potemkin. (2021) Electron Density Analysis of SARS-CoV-2 RNA-Dependent RNA Polymerase Complexes. Molecules 26:13, pages 3960.
Crossref
Crossref
Aliye Gediz Erturk, Arzu Sahin, Ebru Bati Ay, Emel Pelit, Emine Bagdatli, Irem Kulu, Melek Gul, Seda Mesci, Serpil Eryilmaz, Sirin Oba Ilter & Tuba Yildirim. (2021) A Multidisciplinary Approach to Coronavirus Disease (COVID-19). Molecules 26:12, pages 3526.
Crossref
Crossref